Page last updated: 2024-10-29

amrinone and Cardiac Septal Defect

amrinone has been researched along with Cardiac Septal Defect in 1 studies

Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.

Research Excerpts

ExcerptRelevanceReference
"With this dosage regimen, amrinone provides a higher cardiac output, more favorable oxygen dynamics, and lower pulmonary vascular resistance than dopamine and nitroglycerin."2.68Amrinone versus dopamine-nitroglycerin after reconstructive surgery for complete atrioventricular septal defect. ( Happonen, JM; Korpela, R; Laitinen, P; Leijala, M; Peltola, K; Rautiainen, P; Sairanen, H, 1997)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Laitinen, P1
Happonen, JM1
Sairanen, H1
Peltola, K1
Rautiainen, P1
Korpela, R1
Leijala, M1

Trials

1 trial available for amrinone and Cardiac Septal Defect

ArticleYear
Amrinone versus dopamine-nitroglycerin after reconstructive surgery for complete atrioventricular septal defect.
    Journal of cardiothoracic and vascular anesthesia, 1997, Volume: 11, Issue:7

    Topics: Amrinone; Dopamine; Double-Blind Method; Female; Heart Septal Defects; Hemodynamics; Humans; Infant;

1997